Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931681 | 0.83 | ALDH1A1 (0.52) | KDM4ERXFP1L3MBTL1MEN1KMT2A | |
| SCHEMBL2046583 | 0.83 | ALDH1A1 (0.52) | KDM4ERXFP1L3MBTL1MEN1KMT2A | |
| SCHEMBL8502354 | 0.82 | CYP2A6 (0.50) | KDM4ERXFP1MEN1KMT2AMAPT | |
| SCHEMBL7934456 | 0.81 | CYP1A2 (0.45) | CYP2A6STING1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL5713 | 0.80 | MEN1 (0.43) | KDM4EL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL129594 | 0.80 | AMY1A (0.51) | KDM4EL3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL7928059 | 0.80 | NQO1 (0.50) | KDM4EL3MBTL1MAPTCYP2A6STING1 | |
| SCHEMBL14733962 | 0.80 | STING1 (0.37) | KDM4EMEN1KMT2AMAPTCYP2A6 | |
| SCHEMBL9381604 | 0.75 | CA12 (0.52) | KDM4ERXFP1L3MBTL1MEN1KMT2A | |
| SCHEMBL8147509 | 0.75 | MAPT (0.46) | KDM4ERXFP1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364321-B1 | HCV inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2331552-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2364321-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2331552-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100272674-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-28 | — | — | US | disclosed |
| US-20100272674-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-28 | — | — | US | disclosed |
| US-20100272674-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-28 | — | — | US | disclosed |
| WO-2010065577-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065577-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010036551-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036551-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | KDM4E 3825/4885RXFP1 4800/4885L3MBTL1 4137/4885 |
| US-20100272674-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | KDM4E 4022/4885RXFP1 4774/4885L3MBTL1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.